DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Centers for Disease Control and Prevention

February 12, 2010

Centers for Disease Control and Prevention (CDC) *Mycobacterium tuberculosis* and Non-tuberculosis Mycobacteria Drug Susceptibility Testing Model Performance Evaluation Program

Subject: Preliminary Report for Panel Shipment November 9, 2009

Dear Participant:

Attached you will find the preliminary susceptibility testing results for the cultures of *M. tuberculosis* sent to you November 9, 2009. These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although the Centers for Disease Control and Prevention (CDC) recommends the radiometric method for routine *M. tuberculosis* drug susceptibility testing, this preliminary report provides the results used in the conventional (agar proportion) method except in the case of pyrazinamide. Participants should use the equivalent radiometric concentrations to determine their results.

This preliminary report will provide you with timely information about the cultures sent to your laboratory. A detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of five (5) *M. tuberculosis* isolates will be emailed to you before the next scheduled shipment. For additional information or to comment on this report, you may contact Angela Ragin at 1-888-465-6062 or aragin@cdc.gov or Sandra Neal at 404 498-2238 or sneal@cdc.gov.

We appreciate your support and participation in the *M. tuberculosis* and NTM Drug Susceptibility Testing Model Performance Evaluation Program.

Sincerely yours,

Angela Ragin, PhD
Project Coordinator
NCPDCID/DLS Mailstop G-23,
Centers for Disease Control and Prevention
Ph: 404 498-2241 Fx: 404 498-2215
email: aragin@cdc.gov

Sandra W. Neal, B.S., MT(ASCP), M.S., P.M.P.
Project Manager
NCPDCID/DLS Mailstop G-23,
Centers for Disease Control and Prevention
Ph: 404 498-2238 Fx: 404 498-2215
email: sneal@cdc.gov

Preliminary Report

Susceptibility Testing Results:
M. tuberculosis Isolates
Panel Shipment November 9, 2009

STRAIN	DRUG RESISTANCE
O	Rifampin resistant at 1.0 µg/ml
P	INH resistant at 0.2 µg/ml and 1.0 µg/ml and ethambutol resistant at 5.0 µg/m
Q	Fully susceptible for primary drugs; resistant to kanamycin at 5.0, capreomycin at 10.0, amikacin at 5.0 µg/ml
R	Fully susceptible
S	Fully susceptible to primary drugs; resistant to ofloxacin at 2.0 µg/ml and to ciprofloxacin at 2.0 µg/ml